Rocket Pharmaceuticals Prices Public Offering of Common Stock

NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) today announced
the pricing of an underwritten public offering of 3,550,000 shares of
its common stock at a public offering price of $15.50 per share. The
gross proceeds to Rocket from the offering are expected to be
approximately $55 million, before deducting the underwriting discounts
and commissions and other estimated offering expenses. Rocket has
granted the underwriters a 30-day option to purchase up to an additional
532,500 shares of its common stock.

All the shares in the offering are to be sold by Rocket. The offering is
expected to close on or about November 30, 2018, subject to satisfaction
of customary closing conditions. Rocket intends to use the net proceeds
from this offering to fund the continued development of its pipeline of
gene therapies for rare diseases, enhancements to in-house
manufacturing, and general corporate purposes.

BofA Merrill Lynch, Cowen and Evercore ISI are acting as joint
book-running managers for the offering. Oppenheimer Co. is acting as
lead manager and Ladenburg Thalmann is acting as co-manager.

In addition to the shares sold in the public offering, Rocket announced
the concurrent sale of 967,742 shares of common stock at a price of
$15.50 per share, for gross proceeds of approximately $15 million, in a
private placement to RTW Investments, LP, an existing stockholder of the
Company and an affiliate of Roderick Wong, the chairman of Rocket’s
board of directors. The sale of these shares will not be registered
under the Securities Act of 1933, as amended, and such shares will be
subject to customary resale restrictions. Additionally, RTW has signed a
90-day lock-up with respect to all shares of Rocket beneficially held by

The public offering is being made by Rocket pursuant to an effective
shelf registration statement on Form S-3 that was previously filed with
the U.S. Securities and Exchange Commission (the “SEC”) and declared
effective by the SEC. A final prospectus supplement relating to and
describing the terms of this offering will be filed with the SEC. When
available, copies of the final prospectus supplement and the
accompanying prospectus relating to these securities may be obtained
from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, Third
Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by
email at,
Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or
by telephone at (631) 274-2806 and Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY
10055, by telephone at 888-474-0200, or by email at
You may also obtain these documents free of charge by visiting the SEC’s
website at

This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or

Forward-looking Statements

Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation,
Rocket’s expectations regarding the consummation of the offerings and
the satisfaction of customary closing conditions with respect to the
offerings and the anticipated use of the net proceeds of the offerings,
may constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of
1995 and other federal securities laws and are subject to substantial
risks, uncertainties and assumptions. You should not place reliance on
these forward-looking statements, which often include words such as
“anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“seek,” “should,” “suggest,” “target,” “will,” “will give,” “would,” or
similar terms, variations of such terms or the negative of those terms.
Although Rocket believes that the expectations reflected in the
forward-looking statements are reasonable, Rocket cannot guarantee such
outcomes. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including, without limitation, changes as a result of market
conditions or for other reasons, the risk that the offerings will not be
consummated, and the impact of general economic, industrial or political
conditions in the United States or internationally, as well as those
risks more fully discussed in the section entitled “Risk Factors” in
Rocket’s Annual Report on Form 10-K for the year ended December 31,
2017. Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of the
date made, and Rocket undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.